Current research:
Since 2022, the resurgence of Poxviridae-related infections—most notably Monkeypox (MPOX)—has reemerged as a significant global public health threat. This alarming trend has underscored the urgent need for the development of effective therapeutics capable of curbing viral spread and reducing disease burden. Our research is focused on the rational design and development of neutralizing antibodies and nanobodies against poxviruses, with a particular emphasis on MPOX.
Our central strategy involves the identification and characterization of potent neutralizing antibodies and nanobodies that specifically target antigenic envelope proteins of poxviruses. These surface-exposed proteins play critical roles in viral entry and pathogenesis, making them prime candidates for therapeutic intervention. By focusing on these antigens, our goal is to interfere with key viral-host interactions, thereby neutralizing infectivity at an early stage.
This multidisciplinary workflow integrates structural biology, molecular virology, protein engineering, and immunological assays to provide a robust platform for the development of next-generation antiviral therapeutics. Ultimately, our work aims to deliver safe and effective antibody-based interventions against MPOX and related poxviruses, addressing a critical unmet need in the field of infectious disease control.